Soliton (Nasdaq: SOLY) is a pre-revenue stage medical device company with a novel and proprietary platform technology licensed from The University of Texas M.D. Anderson Cancer Center ("MD Anderson"). The Company's first commercial product will utilize rapid pulses of designed acoustic shockwaves to accelerate the removal of unwanted tattoos dramatically. We are based in Houston, Texas. Our RAP device uses designed acoustic shockwaves to accelerate the removal of tattoos when used in conjunction with existing lasers. Our technology allows a doctor to treat a patient multiple times in a single office visit and significantly reduce the overall time it takes to remove a tattoo. Clinical trial data suggest that the “Soliton†method can enable tattoo removal in just 1/3 of the time of current methods. While we are initially targeting the tattoo removal market, our technology also shows promise in several other indications, including reduction of cellulite, skin laxity, and subcutaneous fat.